Roche

News

Roche's Tecentriq loses bladder cancer use as FDA crackdown ...

Roche's Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that have failed to live up to their early promise.

News

Double first for Scotland as it backs Roche’s Rozlytrek, Nov...

The Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment of solid tumours with NTRK gene fusion mutations, regardless of where they o

R&D

Roche on COVID-19 healthcare and testing: the pharmaphorum p...

For episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Ireland at Roche Diagnostics, about the pressure COVID-19 has put on healthcare systems.

News

Roche and PatchAi partner on digital tool for cancer patient...

Roche’s Italian subsidiary has joined forces with digital health startup PatchAi to roll out an app that aims to support people diagnosed with cancer.

News

Roche targets wet AMD with faricimab and its 16-week regimen

Twin late-stage trials of Roche’s ophthalmology drug faricimab have hit the mark in “wet” age-related macular degeneration trial, as the company’s challenge to rivals from Novartis and Baye

Market Access

NICE rejects BMS' Zeposia MS pill in provisional guidance

NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance.

Roche's Tecentriq loses bladder cancer use as FDA crackdown ...

Double first for Scotland as it backs Roche’s Rozlytrek, Nov...

Roche on COVID-19 healthcare and testing: the pharmaphorum p...

Roche and PatchAi partner on digital tool for cancer patient...

Roche targets wet AMD with faricimab and its 16-week regimen

NICE rejects BMS' Zeposia MS pill in provisional guidance

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks